Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: Results from a U.S. case-control study

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 4, 2004, Pages 607-612

  Lacey Jr , James V ^a   Potischman, Nancy ^a   Madigan, M Patricia ^a   Berman, Michael L ^b   Mortel, Rodrigue ^c   Twiggs, Leo B ^d   Barrett, Rolland J ^e   Wilbanks, George D ^f   Lurain, John R ^g   Fillmore, Capri Mara ^a   Sherman, Mark E ^a   Brinton, Louise A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d University of Minnesota   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARCINOGENESIS; CASE CONTROL STUDY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LOGISTIC MODELS; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; UNITED STATES;

EID: 2942517650     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer, 1988;57:205-12.
2. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomark Prev, 2002;11:1531-43.
3. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst, 1996;88:1127-35.
4. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer, 2001;84:975-81.
5. Austin H, Drews C, Partridge EE. A case-control study of endometrial cancer in relation to cigarette smoking, serum estrogen levels, and alcohol use. Am J Obstet Gynecol, 1993;169:1086-91.
6. Potischman N, Gail MH, Troisi R, Wacholder S, Hoover RN. Measurement error does not explain the persistence of a body mass index association with endometrial cancer after adjustment for endogenous hormones. Epidemiology, 1999;10:76-9.
7. Rutanen EM. Insulin-like growth factors in endometrial function. Gynecol Endocrinol, 1998;12:399-406.
8. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 2000;92:1472-89.
9. Rosen CJ, Pollak M. Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab, 1999;10:136-41.
10. Liu HC, He ZY, Mele C, Damario M, Davis O, Rosenwaks Z. Hormonal regulation of expression of messenger RNA encoding insulin-like growth factor binding proteins in human endometrial stromal cells cultured in vitro. Mol Hum Reprod, 1997;3:21-6.
11. Kleinman D, Karas M, Roberts CT Jr, et al. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology, 1995;136:2531-7.
12. Rutanen EM, Stenman S, Blum W, Karkkainen T, Lehtovirta P, Stenman UH. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab, 1993;77:199-204.
13. Ayabe T, Tsutsumi O, Sakai H, et al. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J, 1997;44:419-24.
14. Petridou E, Koukoulomatis P, Alexe DM, Voulgaris Z, Spanos E, Trichopoulos D. Endometrial cancer and the IGF system: a case-control study in Greece. Oncology, 2003;64:341-5.
15. Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R. Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer, 2003;89:1697-704.
16. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer, 2004;108:262-8.
17. Troisi R, Potischman N, Hoover RN, Siiteri P, Brinton LA. Insulin and endometrial cancer. Am J Epidemiol, 1997;146:476-82.
18. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol, 1992;167:1317-25.
19. Brinton LA, Hoover RN, Endometrial Cancer Collaborative Group. Estrogen replacement therapy and endometrial cancer risk. Unresolved issues. Obstet Gynecol, 1993;81:265-71.
20. Brinton LA, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD. Cigarette smoking and the risk of endometrial cancer. Am J Epidemiol, 1993;137:281-91.
21. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer, 1985;56:403-12.
22. Zhou J, Dsupin BA, Giudice LC, Bondy CA. Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. J Clin Endocrinol Metab, 1994;79:1723-34.
23. Kleinman D, Karas M, Danilenko M, et al. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology, 1996;137:1089-95.
24. Hung H, Pollak M. Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review. Prog Growth Factor Res, 1995;6:495-501.
25. Maiorano E, Loverro G, Viale G, Giannini T, Napoli A, Perlino E. Insulin-like growth factor-I expression in normal and diseased endometrium. Int J Cancer, 1999;80:188-93.
26. Rutanen EM, Nyman T, Lehtovirta P, Ammala M, Pekonen F. Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer, 1994;59:307-12.
27. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc, 2001;60:91-106.
28. Smith GD, Gunnell D, Holly J. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ, 2000;321:847-48.